Cardiol Therapeutics
CRDL
33 hedge funds and large institutions have $5.97M invested in Cardiol Therapeutics in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 7 closing their positions.
68% more capital invested
Capital invested by funds: $3.54M → $5.97M (+$2.42M)
0.88% less ownership
Funds ownership: 11.32% → 10.45% (-0.88%)
6% less funds holding
Funds holding: 35 → 33 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MOS
MGO One Seven
Beachwood,
Ohio
|
+$66K |
| 2 |
TC
Tejara Capital
London,
United Kingdom
|
+$37.3K |
| 3 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$26.4K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$20.2K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$19.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AXS Investments
Port Chester,
New York
|
-$283K |
| 2 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$132K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$46.1K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$29.5K |
| 5 |
RSWM
Robertson Stephens Wealth Management
San Francisco,
California
|
-$13.6K |
CRDL Hedge Fund Activity: Q2 2023 in Review
33 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q2 2023, worth a combined $5.97M — up 68% from $3.54M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CRDL and 5 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 5 added.
The largest buyer was MGO One Seven, opening a new position worth an estimated $66K. The largest seller was AXS Investments, cutting an estimated $283K.
- 33 institutional investors held Cardiol Therapeutics (CRDL) as of Q2 2023, down from 35 in Q1 2023.
- Funds reported $5.97M of Cardiol Therapeutics stock for Q2 2023, up 68% quarter-over-quarter.
- 5 funds opened new Cardiol Therapeutics positions in Q2 2023 and 7 closed out, a net change of -2 holders.
- The largest Cardiol Therapeutics buyer in Q2 2023 was MGO One Seven, an estimated $66K added.
- The largest Cardiol Therapeutics seller in Q2 2023 was AXS Investments, an estimated $283K sold.
Based on aggregated 13F filings for Q2 2023.